← Research library

A new endogenous differentiating factor (myelopeptide-4) for myeloid cells.

Lab research · 2000

What was studied
Human leukemia cell lines; porcine marrow-derived peptide
Main finding
MP-4 (FRPRIMTP), isolated from porcine marrow culture, altered differentiation markers and morphology in HL-60 and K-562 leukemia cell lines. This was not a leukemia treatment trial.

Study data at a glance

Participants or experimental model
Human leukemia cell lines; porcine marrow-derived peptide
Reported results
MP-4 (FRPRIMTP), isolated from porcine marrow culture, altered differentiation markers and morphology in HL-60 and K-562 leukemia cell lines. This was not a leukemia treatment trial.
Study limitations and source details

Study limitations

  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Source details

Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.

Abstract reviewed

Sources checked

Citation

In vitroEnglish abstract

Strelkov LA, Mikhailova AA, Fonina LA, Petrov RV. A new endogenous differentiating factor (myelopeptide-4) for myeloid cells. FEBS letters

Study source ↗ · DOI 10.1016/s0014-5793(00)01344-2 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards